# CaLycia Biosciences **Type:** venture **Status:** Draft **Confidence:** Low **Focus:** macrophage cell therapy, glioblastoma, CNS oncology, solid tumors, immuno-oncology **Stage:** Preclinical; CALYM-001 at in vivo validation, pre-IND target **Location:** Salt Lake City, UT **Updated:** 2026-06-19 **Needs-reviewed:** 2026-06-19 **Hero:** https://picsum.photos/seed/calycia-macrophage-gbm-2026/1600/1100 **Pull:** *Engineered macrophages delivered locally into the brain — a CAR-T alternative built for solid CNS tumors.* **Relates:** cites [Official Website: CaLycia Biosciences](calycia-biosciences-official-website.md) ## Summary CaLycia Biosciences is a Salt Lake City biotechnology company developing macrophage-based cell therapies for aggressive solid tumors of the brain. Its lead program, CALYM-001, targets glioblastoma through local intracranial delivery of engineered macrophages — an approach designed to bypass blood-brain-barrier and solid-tumor microenvironment limits that have constrained systemic CAR-T success. Legacy intake material places the company as a University of Utah spinout from the Roh-Johnson lab, resident in the Altitude Lab ecosystem, with seed support from the Cumming Foundation. The official website confirms Salt Lake City location and preclinical pipeline stage but does not name founders or investors on the pages reviewed. ## Impact Glioblastoma remains one of oncology's hardest indications: median survival is roughly 15 months with limited durable advances over decades. CAR-T has transformed liquid malignancies but has largely failed in solid tumors — partly because T cells struggle to penetrate dense tumor stroma and because solid tumors actively suppress T-cell function. If locally delivered macrophage therapies can migrate through resection margins, phagocytose residual tumor cells, and present antigens to recruit adaptive immunity, they could address a CNS delivery problem that systemic biologics cannot solve. Success in GBM would also validate a platform extension (CALYM-002 for melanoma brain metastasis is listed in early discovery). ## What They Are Building Per the official website, CaLycia's platform has four operational steps: 1. **Engineer** — modify a patient's macrophages with targeting receptors and persistent immune-activating payloads. 2. **Infiltrate** — administer cells locally into the CNS so they migrate through neural tissue and tumor margins. 3. **Remodel** — engulf tumor cells, present antigens locally, and recruit T-cells to convert immunologically "cold" microenvironments. 4. **Scale** — develop short, high-yield ex vivo manufacturing protocols tailored to primary macrophages. The therapeutic pipeline lists **CALYM-001** (glioblastoma, lead intracranial program, in vivo validation, pre-IND target) and **CALYM-002** (melanoma brain metastasis, early discovery). The company states it has robust in-vitro and in-vivo datasets and a scalable ex-vivo production base, and offers secure data-room access to qualified investors and strategic partners. ## What They Need Now Likely needs include cell-therapy process development engineers, macrophage transfection and expansion specialists, neurosurgical and neuro-oncology clinical advisors, IND-enabling study operators, and seed or strategic capital. Macrophage engineering is technically harder than T-cell CAR workflows — shorter ex vivo lifespan and harder genetic modification — so manufacturing and persistence are core risks. ## Who Could Help Useful helpers include CNS cell-therapy regulatory consultants, glioblastoma clinical-trial design advisors, ex vivo cell-manufacturing CRO partners, neurosurgical KOLs for local-delivery protocols, and early-stage biotech investors with immuno-oncology experience. [Altitude Labs](altitude-labs.md) may be relevant infrastructure if the company remains in that incubator ecosystem. ## Utah Context CaLycia is headquartered in Salt Lake City and appears connected to the University of Utah life-sciences spinout pipeline and Altitude Lab — the Recursion–U of U health-care incubator that also hosts companies like [Intactis Bio](intactis-bio.md). Utah's CNS and oncology research base (U of U Huntsman Cancer Institute and related labs) provides academic depth, though no macrophage CAR therapy has reached clinical approval anywhere as of the evidence reviewed here. ## Evidence - [Official Website: CaLycia Biosciences](calycia-biosciences-official-website.md) ## See Also - [Intactis Bio](intactis-bio.md) — another early Altitude Lab–associated Utah biotech spinout - [Altitude Labs](altitude-labs.md) — Utah health-care incubator that may host early life-sciences companies ## Open Questions - Founders, academic PI linkage (Roh-Johnson lab), and Daniel Greiner's role cited in legacy notes are not confirmed on the official website. - Cumming Foundation seed investment terms and amount are not established on the source page reviewed here. - IND filing timeline, specific CAR or receptor engineering approach, and clinical-site strategy are undisclosed publicly. - Independent replication of in-vivo efficacy claims requires peer-reviewed publication or investor data-room verification. - GBM clinical attrition is historically high; platform extension to CALYM-002 depends on lead-program validation. - The placeholder hero should be replaced with a cleared scientific or company image before magazine layout use.